Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 619, pseudogene (RN7SL619P) is a **pseudogene** derived from the gene encoding 7SL RNA, which is a component of the signal recognition particle (SRP) ribonucleoprotein complex[1][3][4][7]. Unlike the functional 7SL RNA genes, RN7SL619P is a nonfunctional, likely truncated genomic sequence that shares homology with 7SL RNA but does not produce a functional transcript or protein[2][3][4][9][8]. Pseudogenes such as RN7SL619P arise through the reverse transcription and reintegration of RNA molecules into the genome, and they accumulate mutations that render them inactive[2][3][4]. The majority of 7SL-like sequences in the human genome are pseudogenes, with only a few remaining as functional 7SL RNA genes[3][4][7]. There are no known therapeutic drugs, biomarker roles, or links to disease for RN7SL619P, and it is not considered a receptor, enzyme, transporter, or other classic drug target class[2][3][4][9][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 619, pseudogene (RN7SL619P).